Regulus Therapeutics
RGLS
#7307
Rank
S$0.72 B
Marketcap
S$10.51
Share price
0.00%
Change (1 day)
432.39%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -S$63.23 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -S$59.52 Million a decrease over its 2023 earnings that were of -S$37.92 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -S$63.23 Million6.23%
2024 -S$59.52 Million56.97%
2023 -S$37.92 Million6.51%
2022 -S$35.6 Million2.53%
2021 -S$34.72 Million93.59%
2020 -S$17.94 Million-15.41%
2019 -S$21.21 Million-64.46%
2018 -S$59.65 Million-33.26%
2017 -S$89.38 Million-13.98%
2016 -S$0.11 Billion44.77%
2015 -S$71.78 Million-1.63%
2014 -S$72.97 Million203.6%
2013 -S$24.04 Million8.65%
2012 -S$22.12 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
S$10.03 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
S$0.57 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$14.59 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
S$19.43 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
S$9.21 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-S$0.15 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-S$0.16 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
S$1.57 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA